Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch

Abstract This case report describes the efficacy of selpercatinib, a selective RET inhibitor, in an unusual case of large-cell neuroendocrine pancreatic carcinoma (LCNEPAC) harboring a CCDC6::RET fusion. A 56-year-old male with a history of multiple lines of systemic therapies exhibited marked clini...

Descripció completa

Dades bibliogràfiques

Autors principals:	Barbara Deschler-Baier, Markus Krebs, Matthias Kroiss, Manik Chatterjee, Daniel Gundel, Christian Kestler, Alexander Kerscher, Volker Kunzmann, Silke Appenzeller, Katja Maurus, Andreas Rosenwald, Ralf Bargou, Elena Gerhard-Hartmann, Vivek Venkataramani
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2024-07-01
Col·lecció:	npj Precision Oncology
Accés en línia:	https://doi.org/10.1038/s41698-024-00659-x
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!